X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (18710) 18710
Book Review (2223) 2223
Publication (1647) 1647
Newsletter (180) 180
Conference Proceeding (64) 64
Book Chapter (46) 46
Magazine Article (41) 41
Book / eBook (17) 17
Dissertation (12) 12
Paper (3) 3
Newspaper Article (2) 2
Trade Publication Article (2) 2
Transcript (2) 2
Presentation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (16676) 16676
humans (12759) 12759
pyridines - therapeutic use (9005) 9005
male (8021) 8021
animals (7087) 7087
pyridines - pharmacology (6356) 6356
female (5938) 5938
middle aged (3976) 3976
pharmacology & pharmacy (3760) 3760
adult (3379) 3379
rats (2943) 2943
aged (2929) 2929
pyridines - administration & dosage (2778) 2778
mice (2650) 2650
pyridines - adverse effects (2392) 2392
oncology (2246) 2246
dose-response relationship, drug (1914) 1914
antineoplastic agents - therapeutic use (1772) 1772
treatment outcome (1757) 1757
cancer (1752) 1752
analysis (1513) 1513
pyridine (1506) 1506
niacinamide - analogs & derivatives (1417) 1417
neurosciences (1378) 1378
phenylurea compounds (1344) 1344
abridged index medicus (1316) 1316
pyridines - chemistry (1275) 1275
pyridines - pharmacokinetics (1212) 1212
protein kinase inhibitors - therapeutic use (1133) 1133
cell line, tumor (1110) 1110
rats, sprague-dawley (1071) 1071
time factors (1068) 1068
care and treatment (1066) 1066
imidazoles - pharmacology (1041) 1041
disease models, animal (1027) 1027
clinical trials as topic (1021) 1021
research (1020) 1020
chemistry, medicinal (1014) 1014
biochemistry & molecular biology (997) 997
benzenesulfonates - therapeutic use (980) 980
drug therapy (973) 973
article (931) 931
administration, oral (930) 930
double-blind method (929) 929
expression (890) 890
pyrazoles - therapeutic use (863) 863
apoptosis (862) 862
antineoplastic agents - pharmacology (858) 858
antineoplastic combined chemotherapy protocols - therapeutic use (815) 815
pyridines (776) 776
drug therapy, combination (769) 769
enzyme inhibitors - pharmacology (764) 764
cell biology (744) 744
chemotherapy (723) 723
medicine & public health (717) 717
structure-activity relationship (716) 716
aged, 80 and over (715) 715
therapy (713) 713
health aspects (709) 709
activation (698) 698
sorafenib (691) 691
lung neoplasms - drug therapy (684) 684
protein kinase inhibitors - pharmacology (683) 683
signal transduction - drug effects (682) 682
cells, cultured (680) 680
drug administration schedule (670) 670
in-vitro (668) 668
cell proliferation - drug effects (661) 661
pharmacology (661) 661
pharmacology/toxicology (659) 659
hiv infections - drug therapy (656) 656
adolescent (655) 655
rats, wistar (652) 652
proteins (645) 645
apoptosis - drug effects (636) 636
cells (616) 616
inhibition (612) 612
psychiatry (603) 603
drug combinations (598) 598
drug interactions (596) 596
pharmacokinetics (595) 595
kinases (587) 587
cardiac & cardiovascular systems (581) 581
phosphorylation (573) 573
signal transduction (568) 568
mutation (549) 549
pyridines - chemical synthesis (547) 547
molecular structure (539) 539
clinical trials (535) 535
atazanavir sulfate (534) 534
nifedipine - therapeutic use (532) 532
piperazines - pharmacology (530) 530
rodents (526) 526
antineoplastic agents - adverse effects (520) 520
toxicology (518) 518
mice, inbred c57bl (516) 516
dabigatran (515) 515
medicine (510) 510
young adult (509) 509
tumors (507) 507
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (17201) 17201
Japanese (443) 443
German (401) 401
French (239) 239
Italian (234) 234
Russian (127) 127
Spanish (113) 113
Chinese (64) 64
Polish (35) 35
Czech (25) 25
Hungarian (21) 21
Portuguese (17) 17
Dutch (15) 15
Danish (14) 14
Swedish (7) 7
Norwegian (6) 6
Ukrainian (5) 5
Croatian (3) 3
Bulgarian (2) 2
Hebrew (2) 2
Romanian (2) 2
Finnish (1) 1
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 482 - 487
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2015, Volume 15, Issue 7, pp. 775 - 784
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with... 
Infectious Disease | INFECTIOUS DISEASES | ABACAVIR-LAMIVUDINE | EFFICACY | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | ACTIVE ANTIRETROVIRAL THERAPY | ONCE-DAILY ATAZANAVIR/RITONAVIR | TWICE-DAILY LOPINAVIR/RITONAVIR | INFECTED PATIENTS | PROTEASE INHIBITORS | TENOFOVIR | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Oligopeptides - therapeutic use | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Pyridines - therapeutic use | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | HIV Protease Inhibitors - therapeutic use | Drug Therapy, Combination - methods | HIV Infections - drug therapy | Zidovudine - therapeutic use | Drug Substitution | Deoxycytidine - analogs & derivatives | Studies | Antiretroviral drugs | Heart attacks | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV | Clinical trials | Infections | Mutation | Drug therapy | Failure | Cost control | Index Medicus
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2014, Volume 161, Issue 7, pp. 461 - 471
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 2, pp. 123 - 129
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
Journal Article